Home » Stocks » STSA

Satsuma Pharmaceuticals, Inc. (STSA)

Stock Price: $6.46 USD 0.00 (0.00%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $6.64 +0.18 (2.79%) Mar 5, 4:28 PM
Market Cap 121.35M
Revenue (ttm) n/a
Net Income (ttm) -45.89M
Shares Out 17.42M
EPS (ttm) -11.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $6.46
Previous Close $6.46
Change ($) 0.00
Change (%) 0.00%
Day's Open 6.50
Day's Range 6.30 - 6.85
Day's Volume 414,331
52-Week Range 3.50 - 36.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 4 days ago

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will...

GlobeNewsWire - 4 days ago

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will par...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroe...

GlobeNewsWire - 4 months ago

- Credit Suisse - 29th Annual Healthcare Conference - November 9 th -1 2 th

Zacks Investment Research - 4 months ago

Satsuma Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Investment Research - 5 months ago

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

The Motley Fool - 5 months ago

Investors are reeling from a late-stage flop for the company's only pipeline candidate.

24/7 Wall Street - 5 months ago

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) has reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, P...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business prog...

GlobeNewsWire - 6 months ago

ASCEND results expected to support STS101 NDA filing in Q4 2021

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed...

GlobeNewsWire - 8 months ago

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

GlobeNewsWire - 9 months ago

More than 1,140 patients randomized and topline results expected in second half 2020 More than 1,140 patients randomized and topline results expected in second half 2020

GlobeNewsWire - 9 months ago

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data  expected in second half of 2020

The Motley Fool - 10 months ago

Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.

Other stocks mentioned: AKBA
GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, P...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial re...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, S...

Benzinga - 1 year ago

Satsuma Pharma (NASDAQ: STSA) made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per share.

About STSA

Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
IPO Date
Sep 13, 2019
CEO
John Kollins
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
STSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for STSA stock is "Hold." The 12-month stock price forecast is 7.25, which is an increase of 12.23% from the latest price.

Price Target
$7.25
(12.23% upside)
Analyst Consensus: Hold